Cytokinetics (CYTK) director Nancy Wysenski granted 75 fully vested shares

Rhea-AI Filing Summary

Cytokinetics, Inc. director Nancy Wysenski reported an acquisition of company stock as equity compensation. On July 15, 2026, she received 75 shares of Common Stock as a fully vested grant under the Cytokinetics Equity in lieu of Cash Retainer Program at an indicated value of $82.6200 per share. Following this grant, she directly holds 33,992 shares of Cytokinetics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wysenski Nancy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	75	$82.62	$6K

Holdings After Transaction: Common Stock — 33,992 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 75 shares Grant value per share: $82.6200 per share Shares owned after transaction: 33,992 shares +1 more

4 metrics

Shares granted 75 shares Common Stock grant to director on 2026-07-15

Grant value per share $82.6200 per share Indicated value for the 75-share equity award

Shares owned after transaction 33,992 shares Total direct holdings of Nancy Wysenski following the grant

Transactions in filing 1 acquisition Single grant, award, or other acquisition reported; no sales

Key Terms

Equity in lieu of Cash Retainer Program, fully vested, Grant, award, or other acquisition

3 terms

Equity in lieu of Cash Retainer Program financial

"granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program."

fully vested financial

"Shares are fully vested at the time of grant."

Grant, award, or other acquisition financial

"transaction code description is Grant, award, or other acquisition."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 04:36 PM Accepted by SEC EDGAR 07/16/2026 - 04:35 PM Learn about SEC filing dates

FAQ

What transaction did Cytokinetics (CYTK) director Nancy Wysenski report on this Form 4?

Director Nancy Wysenski reported an equity grant of 75 shares of Cytokinetics Common Stock. The shares were issued as compensation under an Equity in lieu of Cash Retainer Program and are fully vested at the time of grant.

How many Cytokinetics (CYTK) shares did Nancy Wysenski receive and at what value?

Nancy Wysenski received 75 shares of Cytokinetics Common Stock valued at $82.6200 per share. This was recorded as a grant or award acquisition rather than an open-market purchase or sale transaction.

What are Nancy Wysenski’s total Cytokinetics (CYTK) holdings after this grant?

After the reported grant, Nancy Wysenski directly holds 33,992 shares of Cytokinetics Common Stock. This figure reflects her post-transaction ownership as disclosed in the Form 4 filing’s ownership table.

Was the Cytokinetics (CYTK) stock grant to Nancy Wysenski vested immediately?

Yes. The 75-share grant to Nancy Wysenski is described as fully vested at the time of grant. This means she does not face a future vesting schedule or service condition on these specific shares.

What is the Cytokinetics Equity in lieu of Cash Retainer Program mentioned in the Form 4 for CYTK?

The filing notes that the 75 shares were granted under the Cytokinetics Equity in lieu of Cash Retainer Program. Under this program, directors receive stock instead of cash for their retainer, aligning compensation with equity.

Does the Form 4 for Cytokinetics (CYTK) show any stock sales by Nancy Wysenski?

No. The Form 4 reports only an acquisition coded as a grant, award, or other acquisition. There are no reported sales or dispositions of Cytokinetics Common Stock in this specific filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wysenski Nancy

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A(1)		75	A	$82.62	33,992	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

	/s/ John Faurescu, attorney-in-fact for Ms. Wysenski	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)